RxDoctor Payments Data

Amy Wecker, MD

Infectious Disease · Miami Beach, FLNPI 1801095757

Payments from drug & device makers

$22,677in general payments, 2019–2025

Across 256 payments — averaging $88.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$18K
  • Viiv Healthcare Company$3K
  • Merck$469
  • Janssen Products, LP$300
  • Johnson & Johnson$299
  • Acella Pharmaceuticals, LLC$134
  • plus $328 from 6 others

What the payments were for

  • Consulting fees$13,06058%
  • Travel & lodging$1,7698%
  • Food & beverage$7,53033%
  • Education$3181%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,677 in reported general payments places this provider in the 85th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$19,490
Medicare patients
11
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala54$205,293
CabenuvaCabotegravir/Rilpivirine19$127,363
DescovyEmtricitabine/Tenofov Alafenam34$71,575
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf15$67,621
JulucaDolutegravir/Rilpivirine12$38,453
Ritonavir13$837
Testosterone Cypionate45$574
Liothyronine Sodium17$497
Albuterol Sulfate HfaAlbuterol Sulfate12$413
Vitamin D2Ergocalciferol (Vitamin D2)15$83
Rosuvastatin Calcium16$76
Gabapentin11$57
Losartan Potassium11$29
Metformin Hcl29$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$17,951$276,86888 claims
Viiv Healthcare CompanyCabenuva, Juluca$3,197$165,81531 claims
Janssen Products, LPSymtuza$300$67,62115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →